Mr. Hugh MacNaught reports

VENTRIPOINT MAKES APPLICATION TO AMEND WARRANTS

Ventripoint Diagnostics Ltd. has made an application to the TSX Venture Exchange to extend the expiry date of a total of 2,845,771 common share purchase warrants exercisable at 30 cents. The warrants were originally issued by the company in connection with a private placement financing made to purchasers' resident in Canada, except Quebec, pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 -- Prospectus Exempt Distributions, which closed in two tranches on Oct. 17, 2024, and Nov. 12, 2024 (see press releases on Aug. 29, 2024, Sept. 17, 2024, Oct. 15, 2024, and Nov. 14, 2024).

An aggregate of 2,351,730 warrants issued Oct. 17, 2024, and expiring April 17, 2025, and an aggregate of 494,041 warrants issued Nov. 12, 2024, and expiring May 12, 2024, will now expire on April 17, 2026.

The warrants to be amended do not include warrants issued to finders. All other provisions of the warrants will remain the same and holders will not receive an amended warrant certificate.

The warrant extension is subject to final acceptance by TSXV Exchange.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS+ products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.